<DOC>
	<DOC>NCT01233947</DOC>
	<brief_summary>AFP464 is an investigational agent which may be effective in the treatment of cancer. The purpose of this study is to test the efficacy of AFP464 +/- Faslodex in ER+ breast cancer patients.</brief_summary>
	<brief_title>Study of AFP464 +/- Faslodex in ER + Breast Cancer</brief_title>
	<detailed_description>This is a randomized, open-label study. Patients will be randomized in a 1:1 ratio to single arm AFP464, or AFP464+Faslodex. Patients will be treated until disease progression is noted.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>proven breast cancer, ER+ status; progression on an aromatase inhibitor; measurable disease or evaluable disease with serum CA27.29&gt;=50 U/mL; adequate bone marrow, liver and renal function; DLco grade 0 or 1. HER2 positive, thoracic radiotherapy or symptomatic pulmonary disease, brain metastases,</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>